AI and Molecular Diagnostics Set to Revolutionize Endocarditis Management
Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Endocarditis Market - A Global and Regional Analysis: Focus on Type, Treatment Type, and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.Endocarditis, an infection of the heart's inner lining and valves, is primarily caused by bacteria entering the bloodstream. Diagnosis and treatment involve prolonged antibiotic regimens, blood cultures, imaging, and in severe cases, valve replacement surgery. Technological advancements in diagnostic imaging and minimally invasive cardiac procedures are significantly improving detection and recovery outcomes.Moreover, the rise in healthcare-associated infections, intravenous drug use, and an aging population with prosthetic valves are amplifying disease incidence globally.However, challenges remain in early detection due to nonspecific symptoms, rising antimicrobial resistance, and management complexity in comorbid patients. The integration of AI-assisted echocardiography, molecular diagnostics, and next-generation antibiotics is expected to redefine the landscape of endocarditis management in the coming decade.ImpactTechnological innovations in imaging (such as 3D echocardiography), real-time pathogen detection, and antibiotic therapy optimization are reshaping clinical management. Increased focus on infection control, early intervention, and precision medicine is also enhancing patient outcomes and reducing treatment burden.North America is projected to lead the market owing to advanced healthcare systems, high prevalence of risk factors, and early access to diagnostics and surgical interventions. Europe holds a significant share due to strong infectious disease monitoring and public health programs. The Asia-Pacific region is witnessing the fastest growth, driven by rising cardiovascular burden, increasing access to tertiary care, and government investments in infectious disease control.
How can this report add value to an organization?
Product/Innovation: This report provides comprehensive insights into the current trends in endocarditis, helping companies identify opportunities for drug and technology development. Organizations can leverage these insights to design therapies, medications, and platforms tailored to the needs of patients suffering from endocarditis, improving outcomes and enhancing market penetration.Competitive: A detailed competitive landscape analysis helps organizations benchmark their market standing against key players. By understanding the strengths and weaknesses of competitors, companies can position themselves more effectively in the global endocarditis market.
Key Market Players and Competition SynopsisThe companies profiled in this report have been selected based on their market presence, product portfolio, and competitive positioning in the global endocarditis market.
Demand Drivers and Limitations
Demand Drivers for the Global Endocarditis Market:
Increasing incidence of bloodstream infections and valve-related complications
Advances in diagnostic modalities including imaging and molecular testing
Expansion of minimally invasive cardiac surgeries
Aging population with higher susceptibility to cardiac infections
Limitations for the Global Endocarditis Market:
Diagnostic delays due to symptom overlap with other cardiac conditions
Increasing antimicrobial resistance complicating treatment
High cost and complexity of long-term therapy and surgical management
Leading players in the global endocarditis market include:
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Viatris Inc
Fresenius Kabi
Basilea Pharmaceutica Ltd
Phaxiam
Hikma Pharmaceuticals PLC
Advacare Pharma
Sandoz AG
Key Topics Covered: 1. Global Endocarditis Market: Industry Analysis1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis1.3 Key Market Trends1.3.1 Impact Analysis1.4 Patent Analysis1.4.1 Patent Filing Trend (by Country)1.4.2 Patent Filing Trend (by Year)1.5 Regulatory Landscape1.6 Ongoing Clinical Trials1.7 Market Dynamics1.7.1 Overview1.7.2 Market Drivers1.7.3 Market Restraints1.7.4 Market Opportunities2. Global Endocarditis Market, by Type, $Million, 2023-20352.1 Infective Endocarditis2.2 Non-Infective Endocarditis3. Global Endocarditis Market, by Treatment Type, $Million, 2023-20353.1 Antibiotics3.2 Antifungal Medications3.3 Surgery3.4 Others4. Global Endocarditis Market, by Region, $Million, 2023-20354.1 North America4.1.1 Market Dynamics4.1.2 Market Sizing and Forecast4.1.3 North America Endocarditis Market, by Country4.1.3.1 U.S.4.2 Europe4.2.1 Market Dynamics4.2.2 Market Sizing and Forecast4.2.3 Europe Endocarditis Market, by Country4.2.3.1 U.K.4.2.3.2 France4.2.3.3 Germany4.2.3.4 Italy4.2.3.5 Spain4.3 Asia-Pacific4.3.1 Market Dynamics4.3.2 Market Sizing and Forecast4.3.3 Asia-Pacific Endocarditis Market, by Country4.3.3.1 Japan5. Global Endocarditis Market, Competitive Landscape and Company Profiles5.1 Competitive Landscape5.1.1 Mergers and Acquisitions5.1.2 Partnership, Alliances and Business Expansion5.1.3 New Offerings5.1.4 Regulatory Activities5.1.5 Funding Activities5.2 Company Profiles5.2.1 Overview5.2.2 Top Products / Product Portfolio5.2.3 Top Competitors5.2.4 Target Customers/End-Users5.2.5 Key Personnel5.2.6 Analyst View
For more information about this report visit https://www.researchandmarkets.com/r/936u5s
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News24
34 minutes ago
- News24
Why do African elites seek medical treatment abroad?
Choosing where to seek medical help is a deeply private decision. But the numerous occasions African leaders have sought treatment abroad have thrown the spotlight on local healthcare investment. To a large extent, leaders are responsible for the development of proper health care for the citizens of their countries. The deaths of former leaders Muhammadu Buhari of Nigeria and Edgar Lungu of Zambia in foreign medical facilities have not calmed accusations that African leaders neglect public health systems in their own countries. 'The state of healthcare in Nigeria is deeply concerning. The biggest problem is infrastructure. There are no drugs and functional medical equipment,' Jamila Atiku, a researcher on public health in Nigeria, told DW. Low investment in public health Reasons for medical tourism include a lack of specialised treatment available locally, poorly equipped hospitals and security fears for politicians. READ | Nigeria's former president Buhari dies at 82 Another factor, according to Zimbabwean health rights advocate Chamunorwa Mashoko, is an over-reliance on foreign aid. 'Among African countries, over 32 out of 54 countries are not allocating significant budgets to health. This is motivated by overdependency on donor aid,' he told DW. 'Africa is failing to realise that foreign funding in health is just for diplomacy. Those assisting us with all that aid really has nothing to do with our health challenges,' Mashoko added. African countries receive more than $60 billion (€52 billion) in health funding, representing just a fraction of the total health financing needed for the continent. Under the 2001 Abuja Declaration, African Union (AU) member states committed to end the continent's health financing crisis by pledging to allocate 15% of their annual national budgets to healthcare. But over two decades later, only three countries, Rwanda, Botswana, and Cape Verde, have consistently met or exceeded the target. The World Health Organisation (WHO) reports that over 30 AU member states allocate less than 10% of their budget to healthcare, with some allocating as little as 5% to 7%. 'Nigeria has been fluctuating between 4%-6% of the annual budget,' said Atiku, adding that politicians are only concerned about other infrastructure development projects like roads. 'Doctors and healthcare professionals are always going on strike because they are underpaid.' Inadequate public financing of health has resulted in poorly run, underperforming health systems across many African countries. 'Over-reliance on external funding is highly unsustainable and inconsistent with achieving Universal Health Coverage,' said Itai Rusike, of the Zimbabwe-based Community Working Group on Health. 'The Abuja target of 15% allocation to health has remained an elusive target. It is now outdated given the population increase, huge disease burden and the levels of neglect of infrastructure and health worker retention,' Rusike added. Which medical services are sought abroad A chronic lack of specialised treatment and facilities is driving many African patients to seek medical treatment abroad. The sectors affected include oncology, cardiology, neurology, orthopaedics, organ transplants, fertility, and paediatrics for the management of rare genetic disorders. Over 300 000 Africans travel to India annually for medical services, spending more than $2 billion each year. India is said to be generating more than $6 billion each year from medical tourism. Projections show the Asian country could get $13 billion in medical tourism by 2026 under the 'Heal in India' initiative. Phill Magakoe/Gallo Images According to the African Journal of Hospitality, Tourism and Leisure, Nigerians are estimated to spend $1 billion annually on medical tourism. Sixty percent of that amount is spent on oncology, orthopaedics, nephrology, and cardiology. Additionally, the figure represents almost 20% of the annual public health expenditure that covers the salaries of health workers. An estimated 5 000 Nigerians fly out of the country monthly for medical treatment, many traveling to India. What needs to be done Some African health authorities argue they are doing their best to improve healthcare for their countries. 'There is room for improvement to fund the health sector. We are targeting to ensure by 2027 at least 17 000 primary healthcare facilities are functional in Nigeria,' Nigeria's Minister of State for Health and Social Welfare, Iziaq Adekunle Salako, told DW. 'There is not a health system in the world that is 100%. We believe we are headed in the right direction in implementing solutions.' Health experts say African governments need to build modern health facilities to offer services currently being outsourced abroad. 'Looking up to politicians will not work. Communities need to come together and pull resources to create health care systems that work for them,' health rights advocate Chamunorwa Mashoko told DW. In 2016, the continental lender Afreximbank launched a support facility to build specialised health facilities across Africa to reduce outbound medical tourism. The initial target would focus on establishing a centre of excellence for cancer patients. Tanzania, Nigeria, Kenya and Ghana were identified as suitable to host the facilities.
Yahoo
an hour ago
- Yahoo
Sector Update: Health Care Stocks Mixed in Afternoon Trading
Health care stocks were mixed Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Hea Sign in to access your portfolio
Fox News
an hour ago
- Fox News
Pack Your Bags to Canada
As seen on Gutfeld!, Tom Shillue guest hosts. How much is a medical bill if a bat flies into your mouth? Tom lets you know. Also, vote Republican or pack your bags to Canada. Learn more about your ad choices. Visit FOX News Radio
